What You Should Know:
- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionise healthcare and improve the human condition using molecular science and AI, and Flatiron Health, a leading health-tech company transforming evidence generation through an engaged care network, oncology-specific expertise, and fit-for-purpose scientific methods and tools, today announced a partnership to create a multimodal data offering to support and accelerate biopharmaceutical drug development and patient care.
- As the pioneer in precision medicine and molecular profiling, Caris has created a molecular-rich, real-world database that contains more than 50 petabytes of oncology-specific genomic, transcriptomic, proteomic and imaging data. Caris was the first in the molecular diagnostic industry to provide Whole Exome Sequencing DNA coverage and Whole Transcriptome Sequencing RNA coverage (WES / WTS) for every patient tested.
Accelerating Advancements for Cancer Drug Discovery
Combining the breadth and depth of Caris’ genomic, transcriptomic and imaging database with Flatiron’s industry-leading longitudinal patient data and high-quality clinical outcomes, backed by deep scientific expertise, equips cancer researchers with robust comprehensive real-world data (RWD) offering at scale to power the next wave of cancer therapeutics.
“We are excited to collaborate with Flatiron Health to create a multimodal data offering in support of biopharma’s efforts to bring novel personalized therapeutic interventions to market to ultimately improve the lives of cancer patients,” said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. “In forming this data union, we are able to maximize biological and clinical context to better understand each patient journey.”